Drug effects on CA125 antigen expression and antibody binding to cancer cells. 1991

T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.

CA125 is a high-molecular weight glycoprotein expressed on most serous-type ovarian cancer and some lung adenocarcinoma tissues. The effects of various drugs on the release of CA125 antigen into culture medium and on monoclonal antibody (MAb) binding to cancer cells were studied using 8 human cancer cell lines, all of which expressed CA125 on their cell surfaces. The effect of dexamethasone was seen at as low a concentration as 10(-9) M dexamethasone, and the release of CA125 and the binding of radiolabelled anti-CA125 antibody were completely inhibited after exposure to 10(-7) M dexamethasone. The number of antibody binding sites markedly decreased. In contrast, sodium butyrate increased CA125 expression. These findings were clearly detected in only 3 cancer cell lines and a significant effect was not seen in the 5 other cancer cell lines. Interferon-gamma, examined in 3 cell lines, suppressed in a dose-dependent manner in 2 CA125 expression cell lines, but enhanced it in one line. No apparent effects were seen after exposure to tissue necrosis factor or interleukin-2. These results suggest that drugs may regulate the CA125 antigen expression in some, but not all, cancer cells and may affect the biodistribution of radiolabelled MAbs.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D003994 Bucladesine A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed) Dibutyryl Adenosine-3',5'-Monophosphate,Dibutyryl Cyclic AMP,(But)(2) cAMP,Bucladesine, Barium (1:1) Salt,Bucladesine, Disodium Salt,Bucladesine, Monosodium Salt,Bucladesine, Sodium Salt,DBcAMP,Dibutyryl Adenosine 3,5 Monophosphate,N',O'-Dibutyryl-cAMP,N(6),0(2')-Dibutyryl Cyclic AMP,AMP, Dibutyryl Cyclic,Adenosine-3',5'-Monophosphate, Dibutyryl,Cyclic AMP, Dibutyryl,Dibutyryl Adenosine 3',5' Monophosphate,Disodium Salt Bucladesine,Monosodium Salt Bucladesine,N',O' Dibutyryl cAMP,Sodium Salt Bucladesine

Related Publications

T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
February 2006, Cellular & molecular immunology,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
March 2004, The Journal of biological chemistry,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
January 1979, Current topics in developmental biology,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
December 1987, Cancer research,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
December 2009, Gynecologic oncology,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
November 2018, European journal of immunology,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
August 1988, European journal of cancer & clinical oncology,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
June 1996, Japanese journal of cancer research : Gann,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
May 2016, The Journal of biological chemistry,
T Nakai, and K Endo, and M Hosono, and T Saga, and Y Watanabe, and H Sakahara, and K Imai, and A Yachi, and Y Kiyozuka, and I Ishiwata
August 2017, Oncotarget,
Copied contents to your clipboard!